Anti-hormone Therapy

More documents

Recommendations

Info

Contents Overview R.H.Bradbury ............................... 1 Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer J.Hoffmann·A.Sommer.......................... 19 Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK E. M. Wallace · T. C. Yeh · E. R. Laird · J. F. Blake · J. Lyssikatos . . . . . . 83 Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic D.W.End·L.Mevellec·P.Angibaud ................... 133 Survival Signaling C.Garcia-Echeverria............................ 169 Progress in the Development of Agents to Control the Cell Cycle K.J.Moriarty·H.Koblish·D.L.Johnson·R.A.GalemmoJr . . . . . . 207 HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit P.tenHolte·K.VanEmelen·M.Janicot·P.C.Fong J.S.deBono·J.Arts ............................ 293 Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy K.Paz·Z.Zhu ............................... 333 Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy T.K.Sawyer................................. 383
XIV Contents Bcr-Abl Kinase Inhibitors D.H.Boschelli ............................... 407 Author Index Volume 1 .......................... 445 Subject Index ................................ 447
Page 2 and 3: 1 Topics in Medicinal Chemistry Edi
Page 4 and 5: Drug research requires interdiscipl
Page 6 and 7: Topics in Medicinal Chemistry Also
Page 8 and 9: Preface to Volume 1 With supreme ir
Page 12 and 13: Top Med Chem (2007) 1: 1-17 DOI 10.
Page 14 and 15: Overview 3 led to animal experiment
Page 16 and 17: Overview 5 electrodes, an effect la
Page 18 and 19: Overview 7 Fig. 3 Acquired capabili
Page 20 and 21: Overview 9 Table 3 Marketed targete
Page 22 and 23: Overview 11 pathways mediating one
Page 24 and 25: Overview 13 Table 4 Targeted drugs
Page 26 and 27: Overview 15 10. Brock N (1989) Canc
Page 28 and 29: Overview 17 83. Daniel KG, Kuhn DJ,
Page 30 and 31: 20 J. Hoffmann · A. Sommer with in
Page 32 and 33: 22 J. Hoffmann · A. Sommer Most ta
Page 34 and 35: 24 J. Hoffmann · A. Sommer classic
Page 36 and 37: 26 J. Hoffmann · A. Sommer Fig. 3
Page 38 and 39: 28 J. Hoffmann · A. Sommer PR is h
Page 40 and 41: 30 J. Hoffmann · A. Sommer activat
Page 42 and 43: 32 J. Hoffmann · A. Sommer of ERα
Page 44 and 45: 34 J. Hoffmann · A. Sommer in brea
Page 48 and 49: 38 J. Hoffmann · A. Sommer cantly
Page 50 and 51: 40 J. Hoffmann · A. Sommer pared w
Page 52 and 53: 42 J. Hoffmann · A. Sommer in the
Page 56 and 57: 46 J. Hoffmann · A. Sommer the syn
Page 58 and 59: 48 J. Hoffmann · A. Sommer ture [1
Page 60 and 61:
50 J. Hoffmann · A. Sommer isation
Page 62 and 63:
52 J. Hoffmann · A. Sommer droloxi
Page 64 and 65:
54 J. Hoffmann · A. Sommer Non-ste
Page 66 and 67:
56 J. Hoffmann · A. Sommer genic,
Page 68 and 69:
58 J. Hoffmann · A. Sommer The pur
Page 70 and 71:
60 J. Hoffmann · A. Sommer cacy of
Page 72 and 73:
62 J. Hoffmann · A. Sommer Fig. 15
Page 74 and 75:
64 J. Hoffmann · A. Sommer Neverth
Page 76 and 77:
66 J. Hoffmann · A. Sommer in the
Page 78 and 79:
68 J. Hoffmann · A. Sommer been de
Page 80 and 81:
70 J. Hoffmann · A. Sommer High-do
Page 82 and 83:
72 J. Hoffmann · A. Sommer Table 1
Page 84 and 85:
74 J. Hoffmann · A. Sommer Blockin
Page 86 and 87:
76 J. Hoffmann · A. Sommer 55. Rod
Page 88 and 89:
78 J. Hoffmann · A. Sommer 122. Hi
Page 90 and 91:
80 J. Hoffmann · A. Sommer 174. Is
Page 92 and 93:
82 J. Hoffmann · A. Sommer 234. Go
Page 94 and 95:
84 E.M. Wallace et al. Abstract App
Page 96 and 97:
86 E.M. Wallace et al. Fig. 1 Targe
Page 98 and 99:
88 E.M. Wallace et al. There are th
Page 100 and 101:
90 E.M. Wallace et al. participates
Page 102 and 103:
92 E.M. Wallace et al. ture, most o
Page 104 and 105:
94 E.M. Wallace et al. Fig. 5 The b
Page 106 and 107:
96 E.M. Wallace et al. 4.1 Selectiv
Page 108 and 109:
98 E.M. Wallace et al. care or supp
Page 110 and 111:
100 E.M. Wallace et al. trials. The
Page 112 and 113:
102 E.M. Wallace et al. in three hu
Page 114 and 115:
104 E.M. Wallace et al. Table 1 Cel
Page 116 and 117:
106 E.M. Wallace et al. 4.2.3 ARRY-
Page 118 and 119:
108 E.M. Wallace et al. HKI-272 inh
Page 120 and 121:
110 E.M. Wallace et al. crease hepa
Page 122 and 123:
112 E.M. Wallace et al. respectivel
Page 124 and 125:
114 E.M. Wallace et al. Fig. 9 Stru
Page 126 and 127:
116 E.M. Wallace et al. end of this
Page 128 and 129:
118 E.M. Wallace et al. compound do
Page 130 and 131:
120 E.M. Wallace et al. 6.2 PD03259
Page 132 and 133:
122 E.M. Wallace et al. sies, but t
Page 134 and 135:
124 E.M. Wallace et al. Despite the
Page 136 and 137:
126 E.M. Wallace et al. are designe
Page 138 and 139:
128 E.M. Wallace et al. 42. Fabian
Page 140 and 141:
130 E.M. Wallace et al. Perrier M,
Page 142 and 143:
132 E.M. Wallace et al. nowski S, O
Page 144 and 145:
134 D.W. End et al. logical maligna
Page 146 and 147:
136 D.W. End et al. growth. In part
Page 148 and 149:
138 D.W. End et al. C-A-A-X recogni
Page 150 and 151:
140 D.W. End et al. Fig. 3 Structur
Page 152 and 153:
142 D.W. End et al. Fig. 5 CAAX pep
Page 154 and 155:
144 D.W. End et al. mediates all of
Page 156 and 157:
146 D.W. End et al. 3.6 FTase Knock
Page 158 and 159:
148 D.W. End et al. acid giving a c
Page 160 and 161:
150 D.W. End et al. Fig. 7 Target d
Page 162 and 163:
152 D.W. End et al. GTase II. Altho
Page 164 and 165:
154 D.W. End et al. Fig. 11 Aryl cy
Page 166 and 167:
156 D.W. End et al. Fig. 14 Structu
Page 168 and 169:
158 D.W. End et al. ness, Chagas di
Page 170 and 171:
160 D.W. End et al. References 1. Q
Page 172 and 173:
162 D.W. End et al. 68. Chen Z, Sun
Page 174 and 175:
164 D.W. End et al. 122. Shaikenov
Page 176 and 177:
166 D.W. End et al. 156. Dinsmore C
Page 178 and 179:
168 D.W. End et al. 201. Gelb MH, V
Page 180 and 181:
170 C. Garcia-Echeverria Keywords H
Page 182 and 183:
172 C. Garcia-Echeverria 2 Insulin-
Page 184 and 185:
174 C. Garcia-Echeverria 2.2 Modula
Page 186 and 187:
176 C. Garcia-Echeverria lesions ar
Page 188 and 189:
178 C. Garcia-Echeverria the divers
Page 190 and 191:
180 C. Garcia-Echeverria Fig. 3 Rep
Page 192 and 193:
182 C. Garcia-Echeverria cal assays
Page 194 and 195:
184 C. Garcia-Echeverria one within
Page 196 and 197:
186 C. Garcia-Echeverria Epidemiolo
Page 198 and 199:
Page 200 and 201:
190 C. Garcia-Echeverria allosteric
Page 202 and 203:
192 C. Garcia-Echeverria Currently,
Page 204 and 205:
194 C. Garcia-Echeverria 24 h. No i
Page 206 and 207:
Page 208 and 209:
198 C. Garcia-Echeverria Fig. 9 PI3
Page 210 and 211:
200 C. Garcia-Echeverria References
Page 212 and 213:
202 C. Garcia-Echeverria 64. Ihle N
Page 214 and 215:
204 C. Garcia-Echeverria 119. Jones
Page 216 and 217:
206 C. Garcia-Echeverria 175. Posad
Page 218 and 219:
208 K.J. Moriarty et al. 3.3.3 Thie
Page 220 and 221:
210 K.J. Moriarty et al. erodimeric
Page 222 and 223:
212 K.J. Moriarty et al. inhibitors
Page 224 and 225:
214 K.J. Moriarty et al. Structure
Page 226 and 227:
216 K.J. Moriarty et al. K i = 0.00
Page 228 and 229:
Page 230 and 231:
220 K.J. Moriarty et al. lectivity
Page 232 and 233:
222 K.J. Moriarty et al. 2.3.5 3,5-
Page 234 and 235:
224 K.J. Moriarty et al. A variety
Page 236 and 237:
226 K.J. Moriarty et al. Fig. 3 Com
Page 238 and 239:
228 K.J. Moriarty et al. a benefici
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
234 K.J. Moriarty et al. This compo
Page 246 and 247:
236 K.J. Moriarty et al. IC 50 = 0.
Page 248 and 249:
Page 250 and 251:
240 K.J. Moriarty et al. over CDK1.
Page 252 and 253:
Page 254 and 255:
244 K.J. Moriarty et al. with an al
Page 256 and 257:
246 K.J. Moriarty et al. Fig. 7 Com
Page 258 and 259:
248 K.J. Moriarty et al. studies, 6
Page 260 and 261:
Page 262 and 263:
252 K.J. Moriarty et al. panies. As
Page 264 and 265:
254 K.J. Moriarty et al. Fig. 10 Di
Page 266 and 267:
256 K.J. Moriarty et al. Fig. 13 Co
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
262 K.J. Moriarty et al. (70% inhib
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
270 K.J. Moriarty et al. of DNA syn
Page 282 and 283:
Page 284 and 285:
274 K.J. Moriarty et al. 4.3.2 Pyri
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
280 K.J. Moriarty et al. 4.3.8 3-Et
Page 292 and 293:
282 K.J. Moriarty et al. 29. Brothe
Page 294 and 295:
284 K.J. Moriarty et al. 81. Yue EW
Page 296 and 297:
286 K.J. Moriarty et al. 122. Brams
Page 298 and 299:
288 K.J. Moriarty et al. Hercend T,
Page 300 and 301:
290 K.J. Moriarty et al. 229. Esced
Page 302 and 303:
Top Med Chem (2007) 1: 293-331 DOI
Page 304 and 305:
HDAC Inhibition in Cancer Therapy 2
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
334 K. Paz · Z. Zhu application of
Page 344 and 345:
336 K. Paz · Z. Zhu mor cells [33-
Page 346 and 347:
338 K. Paz · Z. Zhu of vascular in
Page 348 and 349:
340 K. Paz · Z. Zhu DC101 has been
Page 350 and 351:
342 K. Paz · Z. Zhu cemia. In Marc
Page 352 and 353:
344 K. Paz · Z. Zhu but there were
Page 354 and 355:
346 K. Paz · Z. Zhu effects after
Page 356 and 357:
348 K. Paz · Z. Zhu adverse effect
Page 358 and 359:
350 K. Paz · Z. Zhu the first comp
Page 360 and 361:
352 K. Paz · Z. Zhu detanib doses
Page 362 and 363:
354 K. Paz · Z. Zhu 3.4.4 Neovasta
Page 364 and 365:
356 K. Paz · Z. Zhu monotherapy tr
Page 366 and 367:
358 K. Paz · Z. Zhu 13736), a pote
Page 368 and 369:
360 K. Paz · Z. Zhu Phase I clinic
Page 370 and 371:
362 K. Paz · Z. Zhu 3.4.10 BAY57-9
Page 372 and 373:
364 K. Paz · Z. Zhu stabilization
Page 374 and 375:
366 K. Paz · Z. Zhu cles. Common a
Page 376 and 377:
368 K. Paz · Z. Zhu ovary, and fal
Page 378 and 379:
370 K. Paz · Z. Zhu 6. Creamer D,
Page 380 and 381:
372 K. Paz · Z. Zhu 73. Sato Y, Ka
Page 382 and 383:
374 K. Paz · Z. Zhu 132. Takahashi
Page 384 and 385:
376 K. Paz · Z. Zhu 189. Graeven U
Page 386 and 387:
378 K. Paz · Z. Zhu Hawtin R, Tang
Page 388 and 389:
380 K. Paz · Z. Zhu 287. Carlomagn
Page 390 and 391:
382 K. Paz · Z. Zhu 345. Yu JL, Ra
Page 392 and 393:
384 T.K. Sawyer Keywords Src · Src
Page 394 and 395:
386 T.K. Sawyer Table 2 Some functi
Page 396 and 397:
388 T.K. Sawyer pathways has been l
Page 398 and 399:
390 T.K. Sawyer nate proteins, and
Page 400 and 401:
392 T.K. Sawyer Fig. 6 Some known S
Page 402 and 403:
394 T.K. Sawyer interactions betwee
Page 404 and 405:
396 T.K. Sawyer collagen type-I-ind
Page 406 and 407:
398 T.K. Sawyer AP23451 administrat
Page 408 and 409:
400 T.K. Sawyer ery. This chapter h
Page 410 and 411:
402 T.K. Sawyer 48. Lutz MP, Esser
Page 412 and 413:
404 T.K. Sawyer 96. Nimmanapalli R,
Page 414 and 415:
Top Med Chem (2007) 1: 407-444 DOI
Page 416 and 417:
Bcr-Abl Kinase Inhibitors 409 2 Ima
Page 418 and 419:
Bcr-Abl Kinase Inhibitors 411 3 New
Page 420 and 421:
Bcr-Abl Kinase Inhibitors 413 sista
Page 422 and 423:
Bcr-Abl Kinase Inhibitors 415 3.1.2
Page 424 and 425:
Bcr-Abl Kinase Inhibitors 417 Schem
Page 426 and 427:
Bcr-Abl Kinase Inhibitors 419 Schem
Page 428 and 429:
Bcr-Abl Kinase Inhibitors 421 group
Page 430 and 431:
Bcr-Abl Kinase Inhibitors 423 Altho
Page 432 and 433:
Bcr-Abl Kinase Inhibitors 425 4.4 S
Page 434 and 435:
Bcr-Abl Kinase Inhibitors 427 of CM
Page 436 and 437:
Bcr-Abl Kinase Inhibitors 429 both
Page 438 and 439:
Bcr-Abl Kinase Inhibitors 431 five
Page 440 and 441:
Bcr-Abl Kinase Inhibitors 433 ity o
Page 442 and 443:
Bcr-Abl Kinase Inhibitors 435 cal t
Page 444 and 445:
Bcr-Abl Kinase Inhibitors 437 The l
Page 446 and 447:
Bcr-Abl Kinase Inhibitors 439 44. M
Page 448 and 449:
Bcr-Abl Kinase Inhibitors 441 92. h
Page 450 and 451:
Bcr-Abl Kinase Inhibitors 443 134.
Page 452 and 453:
Author Index Volume 1 Thevolumenumb
Page 454 and 455:
Subject Index Abiraterone 50 Ableso
Page 456 and 457:
Subject Index 449 Hormone response
Page 458:
Subject Index 451 Testosterone 47,
show all

Anti-hormone Therapy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?